Belite Bio, Inc
NASDAQ:BLTE
62 (USD) • At close December 24, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.399 | 0.198 | 0.03 | 0.017 |
| Gross Profit
| -0.399 | -0.198 | -0.03 | -0.017 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 24.844 | 8.869 | 7.419 | 3.688 |
| General & Administrative Expenses
| 6.824 | 3.952 | 2.378 | 2.055 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 |
| SG&A
| 6.824 | 3.952 | 2.378 | 2.055 |
| Other Expenses
| 0 | 0.166 | 0.126 | 0 |
| Operating Expenses
| 31.668 | 12.821 | 9.797 | 5.743 |
| Operating Income
| -31.668 | -12.821 | -9.797 | -5.743 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.045 | 0.173 | 0.131 | -0.009 |
| Income Before Tax
| -31.623 | -12.648 | -9.666 | -5.752 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.009 | -0.173 | 0.126 | 0.001 |
| Net Income
| -31.632 | -12.475 | -9.792 | -5.753 |
| Net Income Ratio
| 0 | 0 | 0 | 0 |
| EPS
| -1.19 | -0.62 | -0.41 | -0.24 |
| EPS Diluted
| -1.19 | -0.62 | -0.41 | -0.24 |
| EBITDA
| -31.529 | -12.434 | -9.636 | -5.714 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 |